Status | Study |
RECRUITING |
Study Name: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Condition: Ewing Sarcoma Date: 2023-11-10 Interventions: Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles.If still on study therapy the participants will con |
RECRUITING |
Study Name: Lurbinectedin in FET-Fused Tumors Condition: Ewing Sarcoma Date: 2023-06-06 Interventions: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days.Doses will be determined in the phase 1 portion of the trial. |
Available |
Study Name: Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma Condition: Ewing Sarcoma Date: 2017-01-20 Interventions: Drug: Ganitumab The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clin |
Recruiting |
Study Name: First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years Condition: Ewing Sarcoma Family of Tumors Date: 2016-12-06 Interventions: Drug: VDC-IE x2 |
Recruiting |
Study Name: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Condition: Ewing's Sarcoma Date: 2016-04-04 Interventions: Biological: pbi-shRNA™ EWS/FLI1 Type 1 LPX Other Name: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex |
Recruiting |
Study Name: Protocol for the Treatment of Metastatic Ewing Sarcoma Condition: Ewing's Sarcoma (ES) Date: 2016-03-23 Interventions: Drug: TEMIRI Window therapy fr |
Recruiting |
Study Name: A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma Condition: Ewing's Sarcoma Date: 2015-07-28 Interventions: Biological: Vigil Vigil 1.0 x |
Completed |
Study Name: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Condition: Relapsed Ewing Sarcoma Refractory Ewing S Date: 2014-08-06 Interventions: Drug: Linsitinib Other Names: OSI-906 ASP7487 |
Recruiting |
Study Name: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma Condition: Ewing Sarcoma Date: 2014-01-21 Interventions: Drug: niraparib Drug: Temozolomide |
Withdrawn |
Study Name: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma Condition: Ewing Sarcoma Date: 2013-10-21 Interventions: Biological: allogeneic stem cell transplantation |